S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NASDAQ:NXTC

NextCure - NXTC Stock Forecast, Price & News

$4.85
+0.14 (+2.97%)
(As of 08/8/2022 05:24 PM ET)
Add
Compare
Today's Range
$4.59
▼
$4.85
50-Day Range
$3.86
▼
$4.94
52-Week Range
$3.25
▼
$9.18
Volume
296,352 shs
Average Volume
150,281 shs
Market Capitalization
$134.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

NextCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
209.3% Upside
$15.00 Price Target
Short Interest
Healthy
4.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.83mentions of NextCure in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.69) to ($2.88) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

295th out of 1,293 stocks

Pharmaceutical Preparations Industry

126th out of 619 stocks

See Top Rated MarketRank™ Stocks Here
NXTC stock logo

About NextCure (NASDAQ:NXTC) Stock

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price objective on shares of NextCure from $21.00 to $13.00 and set an "overweight" rating for the company in a research report on Monday, May 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, NextCure currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

NextCure Price Performance

Shares of NASDAQ:NXTC opened at $4.71 on Monday. The stock's 50-day simple moving average is $4.50 and its two-hundred day simple moving average is $4.65. NextCure has a 52-week low of $3.25 and a 52-week high of $9.18.

NextCure (NASDAQ:NXTC - Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.06). Equities analysts anticipate that NextCure will post -2.69 earnings per share for the current year.

Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Stock News Headlines

August 7, 2022 | seekingalpha.com
NextCure (NXTC) Investor Presentation - Slideshow
August 4, 2022 | seekingalpha.com
NextCure GAAP EPS of -$0.65 beats by $0.09 (NASDAQ:NXTC) - Seeking Alpha
August 4, 2022 | finance.yahoo.com
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
August 3, 2022 | streetinsider.com
Cape Fox Corporation is Leading the Way With a New Innovation Hub - StreetInsider.com
July 6, 2022 | finance.yahoo.com
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
June 27, 2022 | finance.yahoo.com
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM - Yahoo Finance
June 27, 2022 | finance.yahoo.com
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
June 25, 2022 | finance.yahoo.com
We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely
June 22, 2022 | finance.yahoo.com
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
May 31, 2022 | benzinga.com
NextCure (NASDAQ:NXTC), Short Interest Report
May 31, 2022 | benzinga.com
NextCure (NASDAQ:NXTC), Analyst Ratings, Price Targets, Predictions
May 24, 2022 | benzinga.com
Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $13 - Benzinga - Benzinga
May 23, 2022 | seekingalpha.com
CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space - Seeking Alpha
May 11, 2022 | finance.yahoo.com
NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price - Yahoo Finance
May 11, 2022 | finance.yahoo.com
NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price
May 5, 2022 | finance.yahoo.com
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results - Yahoo Finance
May 5, 2022 | finance.yahoo.com
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
May 3, 2022 | finance.yahoo.com
NextCure to Present at the BofA Securities 2022 Healthcare Conference
May 3, 2022 | benzinga.com
NextCure to Present at the BofA Securities 2022 Healthcare Conference - Benzinga - Benzinga
April 19, 2022 | globenewswire.com
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation - GlobeNewswire
April 19, 2022 | finance.yahoo.com
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation
April 17, 2022 | greenwichtime.com
New program changes how Yale turns ideas into business ventures - Greenwich Time
April 5, 2022 | finance.yahoo.com
NextCure to Present at 21st Annual Needham Virtual Healthcare Conference
March 17, 2022 | finance.yahoo.com
What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? - Yahoo Finance
March 15, 2022 | finance.yahoo.com
What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares?
See More Headlines
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Company Calendar

Last Earnings
11/04/2021
Today
8/08/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NXTC
CUSIP
N/A
CIK
1661059
Web
www.nextcure.com
Phone
(240) 399-4900
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+209.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,390,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.66%
Return on Assets
-30.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
32.52
Quick Ratio
32.52

Sales & Book Value

Annual Sales
$22.38 million
Price / Sales
6.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.45 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
27,747,000
Free Float
25,305,000
Market Cap
$134.57 million
Optionable
Not Optionable
Beta
-0.10

Key Executives

  • Mr. Michael S. Richman MSBA (Age 61)
    Co-Founder, CEO, Pres & Director
    Comp: $726.42k
  • Dr. Solomon Langermann Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $527.98k
  • Dr. Han Myint FACP (Age 69)
    M.D., Chief Medical Officer
    Comp: $611.98k
  • Dr. Lieping Chen M.D. (Age 64)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Steven P. Cobourn CPA (Age 59)
    CPA, Chief Financial Officer
  • Dr. Timothy Mayer Ph.D. (Age 57)
    Chief Operating Officer
  • Mr. Sourav Kundu Ph.D. (Age 62)
    Sr. VP of Devel. & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NXTC Stock - Frequently Asked Questions

Should I buy or sell NextCure stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares.
View NXTC analyst ratings or view top-rated stocks.

What is NextCure's stock price forecast for 2022?

5 brokerages have issued 12 month price objectives for NextCure's shares. Their NXTC stock forecasts range from $13.00 to $17.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 213.2% from the stock's current price.
View analysts price targets for NXTC or view top-rated stocks among Wall Street analysts.

How has NextCure's stock price performed in 2022?

NextCure's stock was trading at $6.00 at the start of the year. Since then, NXTC shares have decreased by 20.2% and is now trading at $4.79.
View the best growth stocks for 2022 here.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NXTC earnings forecast.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.02.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.39%) and Connor Clark & Lunn Investment Management Ltd. (0.24%).
View institutional ownership trends.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $4.79.

How much money does NextCure make?

NextCure (NASDAQ:NXTC) has a market capitalization of $132.91 million and generates $22.38 million in revenue each year. The company earns $-69,390,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How many employees does NextCure have?

NextCure employs 87 workers across the globe.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The official website for the company is www.nextcure.com. The company can be reached via phone at (240) 399-4900 or via email at ir@nextcure.com.

This page (NASDAQ:NXTC) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.